
Major Scope
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Leukemia
- Bladder Cancer
- Kidney Cancer
- Endometrial Cancer
- Oncology Case Reports
- Radiation Therapy
Abstract
Citation: Clin Oncol. 2017;2(1):1183.DOI: 10.25107/2474-1663-v2-id1183
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
Arvind Jain, Jing Zhang and Terence Rabbitts
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
*Correspondance to: Terence Rabbitts
PDF Full Text Review Article | Open Access
Abstract:
Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option.
Keywords:
Ewing sarcoma; Chromosomal translocation; Antibody; Single domains; iDAb; LINGO-1; ADC; Nanoparticles
Cite the Article:
Jain A, Zhang J, Rabbitts T. LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma. Clin Oncol. 2017;2: 1183.
Journal Basic Info
- Impact Factor: 3.231**
- H-Index: 11
- ISSN: 2474-1663
- DOI: 10.25107/2474-1663
- PubMed NLM ID: 101705590